Treatment Study for Individuals at Risk for Frontemporal Dementia
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Brain and Nervous System, Dementia
Study Purpose
This study will test an experimental drug called AL001 for the treatment of individuals who have a progranulin gene mutation that causes frontotemporal dementia (FTD). An experimental drug is a drug, or a form of a drug, that is not yet approved by regulatory authorities.
Who Can Participate
Age: 18-85 years old
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
- UH IRB: SITE00001197
- StudyID: 2020-0182
- ClinicalTrials.gov: NCT04374136
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422